Cabaletta Bio (CABA) Expected to Announce Quarterly Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) is projected to post its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.4579) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.

Cabaletta Bio Price Performance

CABA stock opened at $3.32 on Wednesday. The company has a market cap of $319.58 million, a price-to-earnings ratio of -1.31 and a beta of 3.25. The company has a fifty day moving average price of $2.70 and a 200 day moving average price of $2.44. Cabaletta Bio has a 12 month low of $0.99 and a 12 month high of $3.78.

Insiders Place Their Bets

In other Cabaletta Bio news, insider Steve Gavel acquired 22,170 shares of the business’s stock in a transaction on Wednesday, January 21st. The stock was purchased at an average price of $2.27 per share, for a total transaction of $50,325.90. Following the completion of the transaction, the insider owned 22,170 shares of the company’s stock, valued at $50,325.90. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven Nichtberger bought 45,000 shares of Cabaletta Bio stock in a transaction on Wednesday, January 21st. The stock was acquired at an average cost of $2.24 per share, with a total value of $100,800.00. Following the acquisition, the chief executive officer owned 1,031,483 shares of the company’s stock, valued at $2,310,521.92. This trade represents a 4.56% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 127,668 shares of company stock valued at $286,211 over the last 90 days. 11.25% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cabaletta Bio

Large investors have recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV purchased a new stake in Cabaletta Bio during the fourth quarter worth about $58,000. Comerica Bank lifted its position in shares of Cabaletta Bio by 2,292.1% during the 1st quarter. Comerica Bank now owns 41,599 shares of the company’s stock valued at $58,000 after acquiring an additional 39,860 shares during the period. LPL Financial LLC purchased a new stake in shares of Cabaletta Bio during the 4th quarter worth approximately $93,000. Tower Research Capital LLC TRC grew its holdings in shares of Cabaletta Bio by 695.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 51,036 shares of the company’s stock worth $78,000 after acquiring an additional 44,621 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Cabaletta Bio in the 4th quarter worth approximately $113,000.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.25.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.